IE
COYA icon

Israel Englander’s Coya Therapeutics COYA Stock Holding History

Israel Englander’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,837
Closed -$121K – 5809
2025
Q4 		$121K Buy
+20,837
New +$127K ﹤0.01% 5600

Other funds holding COYA

DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Israel Englander's COYA Position: Q1 2026 in Review

Israel Englander sold out of Coya Therapeutics (COYA) in Q1 2026, closing a stake of 20,837 shares — an estimated $121K sold.

Israel Englander first reported a position in COYA in Q4 2025 and held it in 1 quarter. The position peaked at $121K in Q4 2025. 56 funds tracked by Wall St. Rank hold COYA as of Q1 2026.

  • Israel Englander reported no remaining Coya Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Israel Englander sold 20,837 Coya Therapeutics shares in Q1 2026, an estimated $121K.
  • Israel Englander first reported a position in Coya Therapeutics in Q4 2025 and held it in 1 quarter.
  • Israel Englander's Coya Therapeutics position peaked at $121K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Coya Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.